Is daily supervised buprenorphine-naloxone dosing necessary?

Robert Kleinman and colleagues examine the efficacy and safety of reducing supervised dosing of sublingual buprenorphine-naloxone for opioid use disorder

Saved in:
Bibliographic Details
Published in:BMJ (Online) 2022-08, Vol.378, p.e071467-e071467
Main Authors: Kleinman, Robert A, Nielsen, Suzanne, Weiss, Roger D
Format: Article
Language:English
Subjects:
Analysis
Buprenorphine
Coronaviruses
COVID-19
Dosage
Drug abuse
Drug addiction
Drug overdose
Drug use
Heroin
Methadone
Naloxone
Narcotics
Pandemics
Pharmacy
Quality of life
Retention
Supervision
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Robert Kleinman and colleagues examine the efficacy and safety of reducing supervised dosing of sublingual buprenorphine-naloxone for opioid use disorder
ISSN:1756-1833
1756-1833
DOI:10.1136/bmj-2022-071467